buspirone has been researched along with Adiadochokinesis in 9 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Buspirone, a 5HT-agonist and D2-dopamine antagonist/agonist, has modest beneficial effects in younger individuals with cerebellar ataxia." | 9.11 | The role of buspirone for the treatment of cerebellar ataxia in an older individual. ( Black, SE; Herrmann, N; Holroyd-Leduc, JM; Liu, BA; Maki, BE; Zecevic, A, 2005) |
| "To evaluate the efficacy of buspirone hydrochloride, a serotonin (5-hydroxytryptamine1A) agonist, in treating patients with cerebellar ataxia." | 9.08 | Use of buspirone for treatment of cerebellar ataxia. An open-label study. ( Gatev, P; Goldfarb, L; Hallett, M; Lou, JS; McShane, L, 1995) |
| "To establish the antiataxic effect of buspirone hydrochloride, a serotonergic 5-hydroxytryptamine1A (5-HT1A) agonist, in a homogenous group of patients characterized by the same well-defined single condition, cerebellar cortical atrophy." | 9.08 | Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. ( Adeleine, P; Dumas, R; Honnorat, J; Laurent, B; Michel, D; Nighoghossian, N; Trouillas, P; Vighetto, A; Xie, J, 1997) |
| "We propose a serotonergic hypothesis for cerebellar ataxia." | 5.29 | [Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication]. ( Adeleine, P; Derex, L; Getenet, JC; Honnorat, J; Nighoghossian, N; Riche, G; Trouillas, P; Xie, J, 1995) |
| "Buspirone, a 5HT-agonist and D2-dopamine antagonist/agonist, has modest beneficial effects in younger individuals with cerebellar ataxia." | 5.11 | The role of buspirone for the treatment of cerebellar ataxia in an older individual. ( Black, SE; Herrmann, N; Holroyd-Leduc, JM; Liu, BA; Maki, BE; Zecevic, A, 2005) |
| "To evaluate the efficacy of buspirone hydrochloride, a serotonin (5-hydroxytryptamine1A) agonist, in treating patients with cerebellar ataxia." | 5.08 | Use of buspirone for treatment of cerebellar ataxia. An open-label study. ( Gatev, P; Goldfarb, L; Hallett, M; Lou, JS; McShane, L, 1995) |
| "To establish the antiataxic effect of buspirone hydrochloride, a serotonergic 5-hydroxytryptamine1A (5-HT1A) agonist, in a homogenous group of patients characterized by the same well-defined single condition, cerebellar cortical atrophy." | 5.08 | Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. ( Adeleine, P; Dumas, R; Honnorat, J; Laurent, B; Michel, D; Nighoghossian, N; Trouillas, P; Vighetto, A; Xie, J, 1997) |
| "We propose a serotonergic hypothesis for cerebellar ataxia." | 1.29 | [Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication]. ( Adeleine, P; Derex, L; Getenet, JC; Honnorat, J; Nighoghossian, N; Riche, G; Trouillas, P; Xie, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takei, A | 1 |
| Hamada, T | 1 |
| Yabe, I | 1 |
| Sasaki, H | 1 |
| Holroyd-Leduc, JM | 1 |
| Liu, BA | 1 |
| Maki, BE | 1 |
| Zecevic, A | 1 |
| Herrmann, N | 1 |
| Black, SE | 1 |
| Lou, JS | 1 |
| Goldfarb, L | 1 |
| McShane, L | 1 |
| Gatev, P | 1 |
| Hallett, M | 1 |
| Trouillas, P | 4 |
| Xie, J | 4 |
| Getenet, JC | 1 |
| Adeleine, P | 4 |
| Nighoghossian, N | 2 |
| Honnorat, J | 2 |
| Riche, G | 1 |
| Derex, L | 1 |
| Michel, D | 1 |
| Vighetto, A | 1 |
| Dumas, R | 1 |
| Laurent, B | 1 |
| Reader, TA | 1 |
| Ase, AR | 1 |
| Le Marec, N | 1 |
| Lalonde, R | 1 |
| Hassin-Baer, S | 1 |
| Korczyn, AD | 1 |
| Giladi, N | 1 |
1 review available for buspirone and Adiadochokinesis
| Article | Year |
|---|---|
Treatment of cerebellar ataxia with 5-HT1A agonist.
Topics: Buspirone; Cerebellar Ataxia; Clinical Trials as Topic; Humans; Serotonin 5-HT1 Receptor Agonists; S | 2005 |
5 trials available for buspirone and Adiadochokinesis
| Article | Year |
|---|---|
The role of buspirone for the treatment of cerebellar ataxia in an older individual.
Topics: Aged, 80 and over; Buspirone; Cerebellar Ataxia; Double-Blind Method; Gait; Humans; Male; Postural B | 2005 |
Use of buspirone for treatment of cerebellar ataxia. An open-label study.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety; Buspirone; Cerebellar Ataxia; Depression; Female; Humans; | 1995 |
Treatment of cerebellar ataxia with buspirone: a double-blind study.
Topics: Adult; Buspirone; Cerebellar Ataxia; Double-Blind Method; Humans; Middle Aged; Placebos; Serotonin R | 1996 |
Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia.
Topics: Anxiety; Atrophy; Buspirone; Cerebellar Ataxia; Cerebellar Cortex; Cerebellum; Humans; Middle Aged; | 1997 |
Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
Topics: Adult; Atrophy; Buspirone; Cerebellar Ataxia; Cerebellum; Double-Blind Method; Humans; Middle Aged; | 1997 |
3 other studies available for buspirone and Adiadochokinesis
| Article | Year |
|---|---|
[Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication].
Topics: Adult; Buspirone; Cerebellar Ataxia; Drug Evaluation; Humans; Serotonin Receptor Agonists; Time Fact | 1995 |
Differential effects of L-trytophan and buspirone on biogenic amine contents and metabolism in Lurcher mice cerebellum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Buspirone; Cerebellar Ataxia; Cerebellum; | 2000 |
An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment.
Topics: Adult; Aged; Amantadine; Buspirone; Cerebellar Ataxia; Clinical Trials as Topic; Disease Progression | 2000 |